KevinMKalinskyMDMS

Oncology • Atlanta, GA

Hematologic Oncology

Associate Professor of Medicine, Winship Cancer Institute at Emory University

Join to view full profile

Dr. Kalinsky is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Kalinsky's full profile

Already have an account?

Office
1365 Clifton Rd NE
Atlanta, GA 30322
Phone+1 404-778-1900

Fax+1 212-305-0178
Is this information wrong?

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2008 - 2009
Tufts Medical CenterFellowship, Hematology and Medical Oncology, 2005 - 2008
Tufts Medical CenterResidency, Internal Medicine, 2002 - 2005
Medical University of South CarolinaClass of 2002

Certifications & Licensure

GA State Medical License 2020 - 2025
NY State Medical License 2008 - 2025
MA State Medical License 2006 - 2008
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Clinical Trials

Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By Surgery Start of enrollment: 2009 Jul 02
Completed
Phase 2
Study of CoQ10 During One Cycle of Doxorubicin Treatment for Breast Cancer Start of enrollment: 2009 Sep 01
Completed
Phase 1
Adjuvant Valproate for High Grade Sarcomas Start of enrollment: 2009 Oct 01
Terminated
Phase 1
Electro-acupuncture for the Prevention of Taxane Induced Myalgias and Neuropathy Start of enrollment: 2010 Dec 01
Completed
Not Applicable
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer Start of enrollment: 2011 Jan 06
Active, not recruiting
Phase 3
MK2206 in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer Start of enrollment: 2011 Apr 01
Terminated
Phase 2
Study of Propranolol in Newly Diagnosed Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy Start of enrollment: 2012 Oct 01
Completed
Phase 2
Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer Start of enrollment: 2013 Oct 01
Completed
Early Phase 1
Ruxolitinib in Combination With Trastuzumab in Metastatic HER2 Positive Breast Cancer Start of enrollment: 2014 Jun 01
Completed
Phase 1, Phase 2
A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer Start of enrollment: 2014 Jul 22
Active, not recruiting
Phase 3
Study of Efficacy of Ribociclib After Progression on CDK4/6 Inhibition in Patients With HR+ HER2- Advanced Breast Cancer Start of enrollment: 2016 Mar 01
Active, not recruiting
Phase 2
ACY-1215 + Nab-paclitaxel in Metastatic Breast Cancer Start of enrollment: 2016 Mar 01
Completed
Phase 1
Testing AZD5363 as a Potential Targeted Treatment in Cancers With AKT Genetic Changes (MATCH-Subprotocol Y) Start of enrollment: 2016 May 31
Active, not recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

Pharmacological suppression of the OTUD4-CD73 proteolytic axis revives antitumor immunity against immune-suppressive breast cancers.
Yueming Zhu, Anupam Banerjee, Ping Xie, Andrey A Ivanov, Amad Uddin, Qiao Jiao, Junlong J Chi, Lidan Zeng, Ji Young Lee, Yifan Xue, Xinghua Lu, Massimo Cristofanilli, ...> ;The Journal of Clinical Investigation. 2024 Mar 26
Final Results From the Randomized Phase III ASCENT Clinical Trial in Metastatic Triple-Negative Breast Cancer and Association of Outcomes by Human Epidermal Growth Fac...
Aditya Bardia, Hope S Rugo, Sara M Tolaney, Delphine Loirat, Kevin Punie, Mafalda Oliveira, Adam Brufsky, Kevin Kalinsky, Javier Cortés, Joyce O' Shaughnessy, Véroniqu...> ;Journal of Clinical Oncology. 2024 Feb 29
3 citations
The HER2-directed antibody-drug conjugate DHES0815A in advanced and/or metastatic breast cancer: preclinical characterization and phase 1 trial results.
Lewis, G., Li, G., Guo, J., Yu, S., Fields, C., Lee, G., Zhang, D., Dragovich, P., Pillow, T., Wei, B., Sadowsky, J., Leipold, D., Wilson, T., Kamath, A., Mamounas, M....> ;Nature Communications. 2024 Jan 11
Randomized adaptive selection trial of cryotherapy, compression therapy, and placebo to prevent taxane-induced peripheral neuropathy in patients with breast cancer.
Accordino, M., Lee, S., Leu, C., Levin, B., Trivedi, M., Crew, K., Kalinsky, K., Raghunathan, R., Faheem, K., Harden, E., Taboada, A., de Oliveira, B., Larson, E., Fra...> ;Breast Cancer Research and Treatment. 2024 Feb 1
1 citations
The role of immune checkpoint inhibition in triple negative breast cancer.
Kidist Tarekegn, Merve Keskinkilic, Tyler J Kristoff, Sean T Evans, Kevin Kalinsky> ;Expert Review of Anticancer Therapy. 2023 Oct 26
4 citations
Radiotherapy Use and Incidence of Locoregional Recurrence in Patients With Favorable-Risk, Node-Positive Breast Cancer Enrolled in the SWOG S1007 Trial.
Reshma Jagsi, William E Barlow, Wendy A Woodward, Eileen Connolly, Reshma Mahtani, Dean Shumway, Corey Speers, Shane R Stecklein, Youssef Zeidan, Hong Zhang, Priyanka ...> ;JAMA Oncology. 2023 Aug 1
5 citations
TROPION-Breast01: Datopotamab deruxtecan vs chemotherapy in pre-treated inoperable or metastatic HR+/HER2- breast cancer.
Aditya Bardia, Komal Jhaveri, Kevin Kalinsky, Sonia Pernas, Junji Tsurutani, Binghe Xu, Erika Hamilton, Seock-Ah Im, Zbigniew Nowecki, Joohyuk Sohn, Michelino De Laure...> ;Future Oncology. 2024 Mar 1
1 citations
Reply to: Ricolinostat is not a highly selective HDAC6 inhibitor.
Jose Silva, Jiyang Yu, Kevin Kalinsky> ;Nature Cancer. 2023 Jun 1
CDK4/6 Inhibition in the Metastatic Setting: Where Are We Headed?
Elizabeth Sakach, Merve Keskinkilic, Sarah Wood, Madison Canning, Kevin Kalinsky> ;Current Treatment Options in Oncology. 2023 Sep 1
Treatment patterns and outcomes associated with sequential and non-sequential use of CDK4 & 6 inhibitors in patients with HR+, HER2- MBC in the real world.
Megan Kruse, Emily Nash Smyth, Lee Bowman, Santosh Gautam, Claudia M Guimaraes, Alnecia R Nisbett, Maxine D Fisher, Zhanglin Lin Cui, Kristin M Sheffield, Kevin Kalinsky> ;Breast Cancer Research and Treatment. 2023 Aug 1
Advances in SERDs and other novel endocrine therapies.
Kevin Kalinsky> ;Clinical Advances in Hematology & Oncology. 2023 Jun 1
10 citations
Randomized Phase II Trial of Endocrine Therapy With or Without Ribociclib After Progression on Cyclin-Dependent Kinase 4/6 Inhibition in Hormone Receptor-Positive, Hum...
Kevin Kalinsky, Melissa K Accordino, Codruta Chiuzan, Prabhjot S Mundi, Elizabeth Sakach, Claire Sathe, Heejoon Ahn, Meghna S Trivedi, Yelena Novik, Amy Tiersten, Geor...> ;Journal of Clinical Oncology. 2023 Aug 20
6 citations
Design of SERENA-6, a phase III switching trial of camizestrant in-mutant breast cancer during first-line treatment.
Nicholas Turner, Cynthia Huang-Bartlett, Kevin Kalinsky, Massimo Cristofanilli, Giampaolo Bianchini, Stephen Chia, Hiroji Iwata, Wolfgang Janni, Cynthia X Ma, Erica L ...> ;Future Oncology. 2023 Mar 1
1 citations
A Discordant Pattern of Uptake on 68 Ga-PSMA PET/CT Versus 18 F-Fluciclovine PET/CT in Radiation-Induced Hepatitis : Implications for Early Postradiotherapy Imaging-Ba...
Omotayo A Adediran, Ismaheel O Lawal, Saima Muzahir, Manali A Bhave, Sarah Friend, Bridget Fielder, Jane Meisel, Mylin A Torres, Toncred M Styblo, Cathy Graham, Anna H...> ;Clinical Nuclear Medicine. 2023 Apr 1
5 citations
Proteolytic regulation of CD73 by TRIM21 orchestrates tumor immunogenicity.
Ziyi Fu, Siqi Chen, Yueming Zhu, Donghong Zhang, Ping Xie, Qiao Jiao, Junlong Chi, Shipeng Xu, Yifan Xue, Xinghua Lu, Xinxin Song, Massimo Cristofanilli, William J Gra...> ;Science Advances. 2023 Jan 6
12 citations
Network-based assessment of HDAC6 activity predicts preclinical and clinical responses to the HDAC6 inhibitor ricolinostat in breast cancer.
Tizita Z Zeleke, Qingfei Pan, Codruta Chiuzan, Maika Onishi, Yuxin Li, Haiyan Tan, Mariano J Alvarez, Erin Honan, Min Yang, Pei Ling Chia, Partha Mukhopadhyay, Sean Ke...> ;Nature Cancer. 2023 Feb 1
14 citations
Trop-2 as a Therapeutic Target in Breast Cancer.
Elizabeth Sakach, Ruth Sacks, Kevin Kalinsky> ;Cancers. 2022 Nov 30
3 citations
Molecular differences between younger versus older ER-positive and HER2-negative breast cancers.
Tao Qing, Thomas Karn, Mariya Rozenblit, Julia Foldi, Michal Marczyk, Naing Lin Shan, Kim Blenman, Uwe Holtrich, Kevin Kalinsky, Funda Meric-Bernstam, Lajos Pusztai> ;NPJ Breast Cancer. 2022 Nov 7
13 citations
Health-related quality of life in the phase III ASCENT trial of sacituzumab govitecan versus standard chemotherapy in metastatic triple-negative breast cancer.
Sibylle Loibl, Delphine Loirat, Sara M Tolaney, Kevin Punie, Mafalda Oliveira, Hope S Rugo, Aditya Bardia, Sara A Hurvitz, Adam M Brufsky, Kevin Kalinsky, Javier Corté...> ;European Journal of Cancer. 2023 Jan 1
2 citations
Racial Disparities in Clinical Outcomes on Investigator-Initiated Breast Cancer Clinical Trials at an Urban Medical Center.
Jeffrey Aldrich, Princess Ekpo, Manali Rupji, Jeffrey M Switchenko, Mylin A Torres, Kevin Kalinsky, Manali A Bhave> ;Clinical Breast Cancer. 2023 Jan 1
3 citations
Patient-centered dosing: oncologists' perspectives about treatment-related side effects and individualized dosing for patients with metastatic breast cancer (MBC).
Anne L Loeser, Lucy Gao, Aditya Bardia, Mark E Burkard, Kevin M Kalinsky, Jeffrey Peppercorn, Hope S Rugo, Martha Carlson, Janice Cowden, Lesley Glenn, Julia Maues, Sh...> ;Breast Cancer Research and Treatment. 2022 Dec 1
21 citations
Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer.
Hope S Rugo, Sara M Tolaney, Delphine Loirat, Kevin Punie, Aditya Bardia, Sara A Hurvitz, Joyce O'Shaughnessy, Javier Cortés, Véronique Diéras, Lisa A Carey, Luca Gian...> ;NPJ Breast Cancer. 2022 Aug 29
1 citations
Study Protocol: Efficacy and Safety of Radioembolization (REM) as an Early Modality (EM) Therapy for Metastatic Breast Cancer (BR) to the Liver with Y90 (REMEMBR Y90).
Richard Wu, Keerthi Gogineni, Jane Meisel, Stephen Szabo, Meenakshi Thirunavu, Sarah Friend, Zachary Bercu, Ila Sethi, Neela Natarajan, Jeffrey Switchenko, Jason Levy,...> ;Cardiovascular and Interventional Radiology. 2022 Nov 1
21 citations
Risk-adapted modulation through de-intensification of cancer treatments: an ESMO classification.
D Trapani, M A Franzoi, H J Burstein, L A Carey, S Delaloge, N Harbeck, D F Hayes, K Kalinsky, L Pusztai, M M Regan, I Sestak, T Spanic, J Sparano, S Jezdic, N Cherny,...> ;Annals of Oncology. 2022 Jul 1
1 citations
Use of a convolutional neural network-based mammographic evaluation to predict breast cancer recurrence among women with hormone receptor-positive operable breast cancer.
Julia E McGuinness, Vicky Ro, Simukayi Mutasa, Samuel Pan, Jianhua Hu, Meghna S Trivedi, Melissa K Accordino, Kevin Kalinsky, Dawn L Hershman, Richard S Ha, Katherine ...> ;Breast Cancer Research and Treatment. 2022 Jul 1
Join now to see all

Journal Articles

Effect of Capivasertib in Patients with an AKT1 E17K-Mutated Tumor
Kevin Kalinsky, Edith P Mitchell, Barbara A Conley, Lyndsay N Harris, Carlos L Arteaga, Alice P Chen, Keith T Flaherty, JAMA Oncology

Lectures

Enhancing Checkpoint Inhibitors in Triple-Negative Breast Cancer. Breast Cancer Immunotherapy: Can We Crack the Code?
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
Phase IB trial of ACY-1215 (Ricolinostat) combined with nab-paclitaxel in metastatic breast cancer.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018

Press Mentions

New Data for ER+ Breast Cancer: Oral SERDs, Pregnancy for Young Patients, and Emerging TargetsJanuary 3rd, 2023
Key Research on TNBC: Top 5 Picks from SABCSDecember 13th, 2022
Study Finds Black Women Have Worst HR+/HER2- Breast Cancer Outcomes of All Racial and Ethnic GroupsDecember 7th, 2022
Join now to see all